Acasti Pharma (ACST) 10-K 22 Jun 21 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2021	Jun. 22, 2021	Sep. 30, 2020
Document Information [Line Items]
Entity Registrant Name	Acasti Pharma Inc.
Entity Central Index Key	0001444192
Trading Symbol	acst
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		208,375,549
Entity Public Float			$ 19,373,829
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Shares, no par value per share

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Current assets:
Cash and cash equivalents	$ 50,942	$ 14,240
Short- term investments	9,789
Receivables	530	546
Assets held for sale	768	2,578
Deferred financing costs		121
Prepaid expenses	343	977
Total current assets	62,372	18,462
Right of Use Asset	86	147
Intangible assets		4,244
Total assets	62,458	22,853
Current liabilities:
Trade and other payables	1,493	7,319
Lease liability	86	76
Total current liabilities	1,579	7,395
Derivative warrant liabilities	5,219	2,393
Lease Liability		71
Total liabilities	6,798	9,859
Common shares	197,194	137,424
Additional paid-in capital	10,817	9,797
Accumulated other comprehensive loss	(6,333)	(7,887)
Accumulated deficit	(146,018)	(126,340)
Total Shareholder’s equity	55,660	12,994
Commitments and contingencies
Total liabilities and shareholders’ equity	$ 62,458	$ 22,853

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues from product sales	$ 196
Operating Expenses
Cost of sales of products	(76)
Research and development expenses, net of government assistance	(4,173)	(15,974)
General and administrative expenses	(5,521)	(5,799)
Sales and marketing	(1,142)	(2,665)
Impairment of Intangible assets	(3,706)
Impairment of Equipment	(1,584)
Impairment of Other assets and prepaid	(413)
Loss from operating activities	(16,419)	(24,438)
Financial Expenses	(3,259)	(1,075)
Net loss and total comprehensive loss	$ (19,678)	$ (25,513)
Basic and diluted loss per share (in dollars per share)	$ (0.17)	$ (0.30)
Weighted average number of shares outstanding (in shares)	118,625,833	84,581,764

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholder's Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Mar. 31, 2019	78,132,734
Balance at Mar. 31, 2019	$ 110,857	$ 8,150	$ (7,135)	$ (100,827)	$ 11,045
Net loss and total comprehensive loss for the period				(25,513)	(25,513)
Cumulative translation adjustment			(752)		(752)
Warrants exercised (in shares)	7,056,103
Warrants exercised	$ 18,810	(262)			18,548
Stock Issued During Period, Shares, New Issues (in shares)	4,065,986
Net proceeds from shares issued under the at-the-market (ATM) program	$ 6,941				6,941
Stock based compensation	$ 78	1,909			1,987
Shares issued as a settlement (in shares)	900,000
Shares issued as a settlement	$ 738				738
Stock based compensation (in shares)	54,626
Balance (in shares) at Mar. 31, 2020	90,209,449
Balance at Mar. 31, 2020	$ 137,424	9,797	(7,887)	(126,340)	12,994
Net loss and total comprehensive loss for the period				(19,678)	(19,678)
Cumulative translation adjustment			1,554		1,554
Warrants exercised (in shares)	222,975
Warrants exercised	$ 274	(91)			183
Stock Issued During Period, Shares, New Issues (in shares)	117,724,769
Net proceeds from shares issued under the at-the-market (ATM) program	$ 59,336				59,336
Stock based compensation	$ 160	1,111			1,271
Balance (in shares) at Mar. 31, 2021	208,375,549
Balance at Mar. 31, 2021	$ 197,194	$ 10,817	$ (6,333)	$ (146,018)	$ 55,660

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows used in operating activities:
Net loss for the year	$ (19,678,000)	$ (25,513,000)
Adjustments:
Amortization of intangible assets	781,000	1,910,000
Depreciation of equipment	143,000	410,000
Impairment of intangible assets	3,706,000
Impairment of Equipment	1,584,000
Impairment of other assets and prepaids	413,000
Stock-based compensation expense	1,174,000	1,953,000
Change in fair value of warrant liabilities	2,426,000	1,116,000
Accretion of interest on convertible debenture		145,000
Write off-of deferred financing costs of at-the-market (ATM) program	264,000
Unrealized exchange loss	814,000	246,000
Changes in non-cash working capital items	(5,971,000)	(2,993,000)
Changes in other assets	25,000	(225,000)
Net cash used in operating activities	(14,319,000)	(22,951,000)
Cash flows from (used in) investing activities:
Acquisition of equipment	(69,000)	(319,000)
Acquisition of short-term investments	(9,810,000)	(1,923,000)
Maturity of short-term investments	21,000	10,380,000
Net cash from (used in) investing activities	(9,858,000)	8,138,000
Cash flows from (used in) financing activities:
Net proceeds from shares issued under the at-the-market (ATM) program	59,332,000	6,981,000
Deferred financing costs	(143,000)	7,000
Proceeds from exercise of warrants	183,000	7,706,000
Proceeds from exercise of stock options	118,000	45,000
Payment of convertible debenture		(1,556,000)
Net cash from financing activities	59,490,000	13,183,000
Effect of exchange rate fluctuations on cash and cash equivalents	6,329,000	(254,000)
Translation effect on cash and cash equivalents related to reporting currency	(4,940,000)	(747,000)
Net (decrease) increase in cash and cash equivalents	36,702,000	(2,631,000)
Cash and cash equivalents, beginning of year	14,240,000	16,871,000
Cash and cash equivalents, end of year	50,942,000	14,240,000
Cash and cash equivalents are comprised of:
Cash	38,406,000	4,869,000
Cash equivalents	$ 12,536,000	$ 9,371,000

Note 1 - Nature of Operations

Note 1 - Nature of Operations	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of Operations Acasti Pharma Inc. (“ Acasti” Corporation” Business Corporations Act 1A Companies Act 3009 102, H7E 2B5. December 2019, In January 2020 August 2020, 3 not not In September 2020, In May 2021 ( 21 third

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of significant accounting policies Basis of presentation These consolidated financial statements of Acasti Pharma Inc., which include the accounts of its subsidiary have been prepared in accordance with U.S. GAAP. All intercompany transactions and balances are eliminated on consolidation. The following summarizes the principal conditions or events relevant to the Corporation's going concern assessment, which primarily considers the period of one The Corporation has incurred operating losses and negative cash flows from operations since its inception. In prior years there was substantial doubt regarding the Corporation's ability to realize its assets and discharge its liabilities and commitments in the ordinary course of business. During year ended March 31, 2021, $59.3 March 31, 2021 $60.7 $1.6 March 31, 2021 The Corporation's ability to continue as a going concern is dependent upon its ability to achieve a successful strategic alternative and ultimately generate cashflows to meet its obligations. To date, the Corporation has financed its operations primarily through public offerings of common shares, private placements, and the proceeds from research tax credits, and will require additional financing in the future. Refer to note 21 no not no one Significant accounting policies, estimates and judgments: The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may Estimates are based on management's best knowledge of current events and actions that management may Estimates and assumptions include the measurement of derivative warrant liabilities ( note 10 note 15 6 7 20 Functional and reporting currency: Effective March 31, 2020, The Corporation's functional currency is the Canadian dollar. The effects of exchange rate fluctuations on translating foreign currency monetary assets and liabilities into Canadian dollars are included in the statement of loss and comprehensive loss as foreign exchange gain/loss. Expense transactions are translated into the U.S. dollar reporting currency at the average exchange rate during the period, and assets and liabilities are translated at end of period exchange rates, except for equity transactions, which are translated at historical exchange rates. Cash and Cash Equivalents: Cash and cash equivalents comprise cash balances and highly liquid investments purchased with original maturities of three Investments: The Corporation's investments consist of term deposits and are classified as held-to-maturity securities. These investments are recorded at amortized cost. Investments with original maturities exceeding three one Receivables: Receivables are classified at amortized cost and recorded at the outstanding amount net of any provisions for uncollectible amount. Deferred Financing Costs: Deferred financing costs consists of fees charged by underwriters, attorneys, accountants, and other fees directly attributable to future issuances of shares. Provided these costs are determined to be recoverable, these costs are deferred and charged subsequently against the gross proceeds of the related equity transaction when it occurs. If at such time, the Corporation deems that these costs are no Assets held for sale: Assets that are classified as held for sale are measured at the lower of their carrying amount or fair value less expected selling costs (“estimated selling price”) with a loss recognized to the extent that the carrying amount exceeds the estimated selling price. The classification is applicable at the date upon which the sale of assets is probable, and the assets are available for immediate sale in their present condition. Assets once classified as held for sale, are not Equipment: (i) Recognition and measurement: Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment and are recognized net within operating expenses in the Consolidated Statement of Loss and Comprehensive Loss. (ii) Subsequent costs: The costs of the day-to-day servicing of equipment are recognized in profit or loss as incurred. (iii) Depreciation: Depreciation is recognized in profit or loss on either a straight-line basis or a declining basis over the estimated useful lives of each part of an item of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets not The estimated useful lives and rates for the current and comparative periods are as follows: Assets Method Period/Rate Furniture and office equipment Declining balance 20% to 30% Computer equipment Declining balance 30% Laboratory equipment Declining balance 30% Production equipment Declining balance 10% to 30% Depreciation methods, useful lives and residual values are reviewed periodically and adjusted prospectively if appropriate. Intangible assets: Intellectual property and licenses that are acquired by the Corporation from a third Amortization group Amortization is calculated over the cost of the intangible asset less its residual value. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows: Assets Period (years) Patents 20 License 8 to 14 Subsequent expenditure: Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures, including expenditure on internally generated goodwill and brands, are recognized in profit or loss as incurred. Research and Development Costs Research and developments expenditures are expensed as incurred. These costs primarily consist of employees' salaries and benefits related to research and development activities, contractors and consultants that conduct the Corporation's clinical trials, independent auditors and consultants to perform investigation activities on behalf of the Corporation, laboratory material and small equipment, clinical trial materials, stock-based compensation expense, and other non-clinical costs and regulatory fees. Advance payments for goods and services that will be used in future research and development are recognized in prepaids or other assets and are expensed when the services are performed, or the goods are used. Impairment of Long-Lived Assets: The Corporation reviews the recoverability of its long-lived assets whenever events or changes in circumstances indicate that it is carrying amount may not first $5,703 March 31, 2021, nil March 31, 2020. Stock based compensation: The Corporation has in place a stock option plan for directors, officers, employees, and consultants of the Corporation, with grants under the stock option plan approved by the Corporation's Board of Directors. The plan provides for the granting of options to purchase Common Shares and the exercise price of each option equals the closing trading price of Common Shares on the day prior to the grant. The terms and conditions for acquiring and exercising options are set by the Corporation's Board of Directors in accordance with and subject to the terms and conditions of the stock option plan. The Corporation measures the cost of such awards based on the fair value of the award at grant date, net of estimated forfeiture, and recognizes stock-based compensation expense in the Consolidated Statements of Loss and Comprehensive Loss on a graded vesting basis over the requisite service period. The requisite service period equals the vesting periods of the awards. The fair value of options is estimated for each tranche of an award that vests on a graded basis. The fair value of options is estimated using the Black-Scholes option pricing model, which uses various inputs including estimated fair value of the Common Shares at the grant date, expected term, estimated volatility, risk-free interest rate and expected dividend yields of the Common Shares. The Corporation applies an estimated forfeiture rate derived from historical employee termination behaviour. If the actual forfeitures differ from those estimated by management, adjustment to compensation expense may Non-employee stock-based compensation transactions in which the Corporation receives goods or services as consideration for its own equity instruments are accounted for as stock-based compensation transactions. The Corporation establishes the fair value at the grant date for non-employee awards and measures the fair value based on the fair value of equity instruments issued. The fair value of a non-employee award is estimated using the Black-Scholes option pricing model, which uses various inputs including estimated fair value of the Common Shares at the grant date, contractual term, estimated volatility, risk-free interest rate and expected dividend yields of the Common Shares. Government grants: Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Corporation has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Grants that compensate the Corporation for expenses incurred are recognized in profit or loss in reduction thereof on a systematic basis in the same years in which the expenses are recognized. Grants that compensate the Corporation for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset. Leases: Adoption of Topic 842 On April 1, 2019, 842. no April 1, 2019, 842 Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may not not The Corporation has elected not one not March 31, 2020, $147. two 8%. $80 Income tax: Income tax expense comprises current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they relate to items recognized directly in equity or in other comprehensive income. Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is recognized in respect of temporary differences between the carrying amounts (tax base) of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax assets and liabilities are measured at the tax rate expected to apply when the underlying asset or liability is realised (settled) based on the rates that are enacted at the reporting date. Deferred tax assets and liabilities are offset if the Corporation has the right to set off the amount owed by with the amount owed by the other party, the Corporation intends to set off and the offset right is enforceable at law. A deferred tax asset is recognized for unused tax losses and tax credits, reduced by a valuation allowance to the extent that it is more likely than not not Earnings per share: The Corporation presents basic and diluted earnings per share ( EPS Segment reporting: An operating segment is a component of the Corporation that engages in business activities from which it may one one $156 March 31, 2020 - $1,510 third Convertible Debentures: The unsecured convertible debentures that existed in the financial statements for the year ended March 31, 2020, February 2020. not not not Derivative financial instruments: The Corporation has issued warrants of which some are accounted for as liability-classified derivatives over its own equity. Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit and loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and all changes in their fair value are recognized immediately in profit or loss as a component of financial expenses. Other equity instruments Warrants that do not Fair Value Measurements Certain of the Corporation's accounting policies and disclosures require the determination of fair value, for both financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. Financial assets and liabilities: In establishing fair value, the Corporation uses a fair value hierarchy based on levels as defined below: · Level 1: · Level 2: · Level 3: no The Corporation has determined that the carrying values of its short-term financial assets and liabilities (cash and cash equivalents, short-term investments and trade and other payables) approximate their fair value given the short-term nature of these instruments. The Corporation measured its derivative warrant liabilities at fair value on a recurring basis using level 3 .

Note 3 - Recent Accounting Pron

Note 3 - Recent Accounting Pronouncements	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	3. Recent Accounting Pronouncements In June 2016, 2016 13 326 2016 13 not 2016 13 December 15, 2022. not

Note 4 - Receivables

Note 4 - Receivables	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	4. Receivables: March 31, 2021 March 31, 2020 Notes $ $ Sales tax receivables 160 301 Government assistance 8 339 209 Interest receivable 13 11 Other receivables 18 25 Total receivables 530 546

Note 5 - Short-term Investments

Note 5 - Short-term Investments	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	5. Short-term Investments: The Corporation holds various marketable securities with maturities greater than 3 March 31, 2021 March 31, 2020 $ $ Term deposits issued in US currency earning interest at ranges between 0.23% and 0.40% and maturing on various dates from June 22, 2021 to July 27, 2021 7,542 - Term deposits issued in CAD currency earning interest at ranges between 0.58% and 0.67% and maturing on various dates from April 16, 2021 to July 27, 2021 2,247 - Total investments 9,789 - Short-term investments 9,789 - Investments - -

Note 6 - Impairment Loss Intang

Note 6 - Impairment Loss Intangible Assets	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	6. Impairment loss Intangible assets: In prior years, the Corporation entered into agreements with Neptune Wellness Solutions Inc. (Neptune) pursuant to which the Corporation obtained a license and exercised its option under this license agreement to pay in advance all of the future royalties payable to Neptune. This license allows the Corporation to exploit the intellectual property rights in-order to develop novel active pharmaceutical ingredients into commercial products for the prescription drugs market. The Corporation tests intangible assets for impairment should circumstances change or events occur that would indicate that the fair value of an asset may second 2021, 3 not 350, In assessing the magnitude of any impairment of the license the Corporation considered all available evidence including i) significant adverse impact from business climate due to Phase 3 not no no not, 3 $3,706 second March 31, 2021, March 31, 2021, $781 2020 $1,910

Note 7 - Assets Held for Sale

Note 7 - Assets Held for Sale	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	7. Assets held for sale: During the period the Corporation committed to a plan and is actively marketing for sale Other assets and Equipment and has met the criteria for classification of assets held for sale: March 31, March 31, $ $ Other assets 387 668 Equipment 381 1,910 768 2,578 a. Other assets Other assets represent krill oil (RKO) held by the Corporation that was expected to be used in the conduct of R&D activities and commercial inventory scale up related to the development and commercialization of the CaPre drug. Given that the development of CaPre will no $413. 3 not b. Equipment March 31, 2021 Cost Accumulated Impairment Net book $ $ $ $ Furniture and office equipment 17 (5 ) - 12 Computer equipment 148 (30 ) (54 ) 64 Laboratory equipment 756 (436 ) (171 ) 149 Production equipment 2,538 (1,023 ) (1,359 ) 156 3,459 (1,494 ) (1,584 ) 381 March 31, 2020 Cost Accumulated Net book value $ $ $ Furniture and office equipment 15 3 12 Computer equipment 64 18 46 Laboratory equipment 684 343 341 Production equipment 2,341 830 1,511 3,104 1,194 1,910 For the year ended March 31, 2021, $143 2020 $410 no 3

Note 8 - Government Assistance

Note 8 - Government Assistance	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Government Assistance [Text Block]	8. Government assistance: March 31, March 31, $ $ Investment tax credit 339 182 Government grant - 27 Total government assistance 339 209 Government assistance is comprised of a government grant from the Canadian federal government and research and development investment tax credits receivable from the Quebec provincial government which relate to qualifiable research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may March 31, 2021, 2020, $127 $149, The amounts recorded as receivables are subject to a government tax audit and the final amounts received may may $ 2029 9 2030 23 2031 36 2032 343 2033 351 2034 347 2035 413 2036 228 2037 251 2038 180 2039 247 2040 369 2041 170 2,967 In September 2019, $750,000 March 31, 2021 $79 In October 2020, $750,000 $326,357.

Note 9 - Trade and Other Payabl

Note 9 - Trade and Other Payables	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	9. Trade and other payables: March 31, 2021 March 31, 2020 $ $ Trade payables 115 1,713 Accrued liabilities and other payables 607 4,247 Employee salaries and benefits payable 771 1,359 Total trade and other payables 1,493 7,319

Note 10 - Derivative Warrant Li

Note 10 - Derivative Warrant Liabilities	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	10. Derivative warrant liabilities: On May 9, 2018, 9,530,000 $1.05 $7.8 CAD$10 9,530,000 9,530,000 one $1.31 May 9, 2023. May 14, 2018, 1,429,500 $1.05 $1.1 $1.5 1,429,500 1,429,500 one $1.31 May 9, 2023. On December 27, 2017, 9,900,990 US$1.01 $10 9,900,990 8,910,891 one nil 892,044 $1.26. The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following tables: Warrants issued May 2018 Warrants issued December 27, 2017 March 31, March 31, March 31, March 31, $ $ $ $ Balance – beginning of year 1,146 6,177 1,247 6,005 Issued during the year - - Amount transferred to Equity - (6,072 ) - (4,770 ) Change in fair value 1,252 1,115 1,174 1 Translation effect 199 (74 ) 201 (11 ) Balance – end of year 2,597 1,146 2,622 1,247 Fair value per warrant issuable 0.39 0.17 0.37 0.18 The fair value of the derivative warrant liabilities was estimated using the Black-Scholes option pricing model and based on the following assumptions: Warrant liabilities issued May 2018 Warrant liabilities issued December 27, 2017 March 31, $ March 31, $ March 31, March 31, Exercise price CAD $1.31 CAD $1.31 USD $1.26 USD $1.26 Share price CAD $0.76 CAD $0.53 USD $0.60 USD $0.38 Risk-free interest 1.39 % 0.66 % 0.92 % 0.37 % Contractual life (years) 2.11 3.11 1.74 2.74 Expected volatility 156.00 % 107.59 % 171.12 % 125.03 % The Corporation measured its derivative warrant liabilities at fair value on a recurring basis. These financial liabilities were measured using level 3 12 . As at March 31, 2021, 5% $241 $257, As at March 31, 2021, 5% $129. 5%

Note 11 - Unsecured Convertible

Note 11 - Unsecured Convertible Debentures	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	11. Unsecured convertible debentures On February 21, 2017, 1,522 2,000 February 21, 2020, 1,052,630 Liability component Equity component Total Private Placement $ $ $ Balance at March 31, 2019 1,361 220 1,581 Accretion of interest on convertible debenture 145 - 145 Translation effect 50 - 50 Shares issued upon exercise of warrants - (33 ) (33 ) Payment upon maturity of debentures (1,556 ) - (1,556 ) Balance at March 31, 2020 - 187 187

Note 12 - Capital and Other Com

Note 12 - Capital and Other Components of Equity	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	12. Capital and other components of equity (a) Common Shares: Authorized capital stock: Unlimited number of shares: Ø Class A shares (Common Shares), voting ( one Ø Class B shares, voting ( ten 5% one one $0.80 none Ø Class C shares, non-voting, non-participating, without par value and maximum annual non-cumulative dividend of 5% one one $0.20 none Ø Class D and E shares, they are non-voting, non-participating, without par value and maximum monthly non-cumulative dividend between 0.5% 2% one one none (b) “At-the-market” sales agreement On February 14, 2019, may $30 may 3 3% 4% June 29, 2020, three may $75,000,000 no may may 3.0% March 31, 2021, 117.7 March 31, 2020 – 4.1 $59.3 March 31, 2020, $7.0 $2.0 March 31, 2020 - $291 $0.52 March 31, 2020 - $1.79 $18 March 31, 2020 - $40 March 31, 2021, $264 (b) Warrants: The warrants of the Corporation are composed of the following: March 31, 2021 March 31, 2020 Number Amount Number Amount $ $ Liability May 2018 public offering warrants 2018 (i) 6,593,750 2,597 6,593,750 1,146 Series December 2017 U.S. public offering warrants 2017 (ii) 7,072,962 2,622 7,072,962 1,247 13,666,712 5,219 13,666,712 2,393 Equity Public offering warrants Public offering broker warrants May 2018 (iii) 1 - 222,976 89 Public offering U.S. broker warrants December 2017 (iv) 259,121 161 259,121 161 Public offering warrants February 2017 (v) 1,723,934 631 1,723,934 631 1,983,056 792 2,206,031 881 (i) Warrant to acquire one $1.31, May 9, 2023. (ii) Warrant to acquire one $1.26, December 27, 2022. (iii) Warrant to acquire one $1.05, May 9, 2023. (iv) Warrant to acquire one $1.2625, December 19, 2022. (v) Warrant to acquire one $2.15, February 21, 2022. During the year ending March 31, 2021, 222,975 May 2018 $0.83 $183 During the year ended March 31, 2020, 235,929 52,288 December 2017 136,013

Note 13 - Revenues

Note 13 - Revenues	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	13. Revenues: In October 2020, 19

Note 14 - Financial Expenses

Note 14 - Financial Expenses	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Other Income and Other Expense Disclosure [Text Block]	14. Financial expenses: March 31, March 31, $ $ Foreign exchange gain (loss) (676) (2 ) Interest payable on convertible debenture - (102 ) Accretion of interest on convertible debenture - (145 ) Financing costs (264 ) (46 ) Interest income 107 336 Change in fair value of warrant liabilities (2,426) (1,116 ) Financial expenses (3,259) (1,075 )

Note 15 - Stock Based Compensat

Note 15 - Stock Based Compensation	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	15. Stock based compensation: At March 31, 2021, (a) Corporation stock option plan: The Corporation has in place a stock option plan for directors, officers, employees, and consultants of the Corporation. An amendment of the stock option plan was approved by shareholders on September 30, 2020. not may 11,719.910 15% April 9, 2019, 14,533,881 15% August 26, 2020. ten twelve 12 thirty-six 36 The total number of shares issued to any one twelve 2% not twelve 2% one twelve 2% The following tables summarize information about activities within the stock option plan: Number of Weighted average Weighted average CAD $ CAD $ Outstanding, March 31, 2019 4,046,677 1.25 0.81 Granted 6,140,517 0.85 0.85 Exercised (30,874 ) 0.81 0.79 Forfeited (212,334 ) 1.62 1.16 Expired (7,500 ) 6.50 3.02 Outstanding, March 31, 2020 9,936,486 1.00 0.83 Granted - - - Exercised (241,750) 0.62 0.47 Forfeited (2,399,817) 0.90 0.74 Expired - - - Outstanding, March 31, 2021 7,294,919 1.04 0.87 Exercisable at end of year 5,025,583 1.17 0.93 March 31, March 31, Weighted average fair value of the options granted to employees and directors of the Corporation - CAD$0.85 Compensation expense recognized under the stock option plan is summarized as follows: March 31, March 31, $ $ Research and development expenses 353 443 General and administrative expenses 828 1,217 Sales and marketing expenses (7) 293 1,174 1,953 As of March 31, 2021, $476 March 31, 2020 – $2,802 1.03 March 31, 2020 - 1.35 A summary of the non-vested stock option activity and related information for the Corporation's stock options granted is as follows: Number of Weighted average CAD ($) Non- vested, March 31, 2020 6,764,252 0.83 Options granted - - Options vested 1,720,280 0.83 Options forfeited and cancelled 2,774,636 0.90 Non- vested, March 31, 2021 2,269,336 0.76 The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for options granted during the periods ended: March 31, 2020 Exercise price $ 0.85 Share price $ 1.09 Dividend — Risk-free interest 0.88 % Estimated life (years) 5.71 Expected volatility 99.11 The following tables summarize the status of the outstanding and exercisable options of the Corporation: March 31, 2021 Exercise price CAD Weighted average remaining contractual life Number of options outstanding Number of options exercisable $ 0.53 – 0.65 8.99 2,418,167 988,167 $ 0.66 – 1.02 7.25 1,527,573 1,300,529 $ 1.03 – 1.42 8.04 1,680,058 1,067,766 $ 1.43 – 1.61 2.11 525,000 525,000 $ 1.62 – 1.71 5.90 108,333 108,333 $ 1.72 – 1.88 6.20 737,500 737,500 $ 1.89 – 3.25 2.16 262,500 262,500 $ 3.26 – 4.65 1.17 22,500 22,500 $ 4.66 – 4.80 1.38 13,288 13,288 7.31 7,294,919 5,025,583 Stock-based compensation payment transactions and broker warrants: The fair value of stock-based compensation transactions is measured using the Black-Scholes option pricing model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historic volatility for a duration equal to the weighted average life of the instruments, life based on the average of the vesting and contractual periods for employee awards as minimal prior exercises of options in which to establish historical exercise experience; contractual life for broker warrants), and the risk-free interest rate (based on government bonds). Service and performance conditions attached to the transactions, if any, are not not may may not (b) Corporation equity incentive plan: The Corporation established an equity incentive plan for employees, directors and consultants. The plan provides for the issuance of restricted share units ( RSUs may no March 31, 2021, March 31, 2020, no March 31, 2021 March 31, 2020.

Note 16 - Loss Per Share

Note 16 - Loss Per Share	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	16. Loss per share: Diluted loss per share was the same amount as basic loss per share, as the effect of options, RSUs and warrants would have been anti-dilutive, as the Corporation has incurred losses in each of the periods presented. All outstanding options, RSUs and warrants could potentially be dilutive in the future.

Note 17 - Supplemental Cash Flo

Note 17 - Supplemental Cash Flow Disclosure	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	17. Supplemental cash flow disclosure: (a) Changes in working capital items: March 31, March 31, $ $ Receivables 58 581 Prepaid expenses 672 (185 ) Trade and other payables (6,701) (3,389 ) Total changes in working capital items (5,971) (2,993 ) (b) Non-cash transactions: March 31, March 31, $ $ ATM transaction costs included in trade and other payables 18 - Shares issued as settlement - 738 Deferred financing costs reclassified to Equity (23) 40 Fair value of derivative warrants liability reclassified to equity - 10,691

Note 18 - Income Taxes

Note 18 - Income Taxes	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	18. Income taxes: Reconciliation of effective tax rate: March 31, March 31, $ $ Loss before income taxes (19,678) (25,513 ) Basic combined Canadian statutory income tax rate 1 26.50% 26.58 % Computed income tax recovery (5,105) (6,781 ) Increase resulting from: Non-deductible stock-based compensation 311 519 Non-deductible change in fair value of warrants 643 205 Change in valuation allowance 4,162 6,004 Other – Foreign exchange (11) 20 Other - 33 Total tax (recovery) expense - - 1 At March 31, 2021 2020, not not not Net deferred income tax assets as of March 31, 2021, 2020 March 31, 2021 March 31, 2020 $ $ Deferred tax assets Tax losses carried forward 28,643 22,052 Research and development expenses 5,424 4,544 Property, plan and equipment 933 324 Intangible assets - 1 Financing expenses 1,167 998 Tax credit carry forwards 2,968 2,468 Other temporary differences 86 76 Deferred tax assets 39,221- 30,463 Deferred tax liabilities Tax basis of unsecured convertible debentures in excess of carrying value - - Deferred tax liabilities - - Valuation allowance (39,221) (30,463 ) Net deferred tax assets - - As at March 31, 2021, March 31, 2021 Federal Provincial $ $ Tax losses carried forward 2028 568 568 2029 1,296 1,290 2030 1,649 1,642 2031 1,800 1,784 2032 1,476 1,453 2033 2,864 2,864 2034 3,658 3,549 2035 4,374 4,374 2036 6,435 6,337 2037 398 394 2038 13,803 13,748 2039 32,252 32,209 2040 23,451 23,315 2041 14,279 14,279 108,303 107,808 Research and development expenses, without time limitation 19,905 21,203 Tax credit carry forwards 2,968 - Other deductible temporary differences, without time limitation 8,249 - Unrecognized tax benefits The following table summarizes the activity related to our gross unrecognized tax benefits for the years ended March 31, 2021 2020: March 31, March 31, $ $ Beginning of year: Increase (decrease) resulting from: Positions taken in the current year - 164 Change in valuation allowance - (164 ) End of year - - The Corporation does not 12

Note 19 - Financial Instruments

Note 19 - Financial Instruments	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	19. Financial instruments: (a) Concentration of credit risk: Financial instruments that potentially subject the Corporation to a concentration of credit risk consist primarily of cash and cash equivalents and investments. Cash and cash equivalents and investments are all invested in accordance with the Corporation's Investment Policy with the primary objective being the preservation of capital and the maintenance of liquidity, which is managed by dealing only with highly rated Canadian institutions. The carrying amount of financial assets, as disclosed in the statements of financial position, represents the Corporation's credit exposure at the reporting date. (b) Foreign currency risk: The Corporation is exposed to the financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates. Foreign currency risk is limited to the portion of the Corporation's business transactions denominated in currencies other than the Corporations functional currency of the Canadian dollar. Fluctuations related to foreign exchange rates could cause unforeseen fluctuations in the Corporation's operating results. The Corporation does not The operating results and financial position of the Corporation are reported in U.S. dollars (reporting currency) in the Corporation's financial statements. (c) Liquidity risk: Liquidity risk is the risk that the Corporation will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Corporation manages liquidity risk through the management of its capital structure and financial leverage. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves the Corporation's operating budgets, and reviews material transactions outside the normal course of business. Refer to Note 2 The Corporation's financial liabilities obligations include trade and other payables, which fall due within the next 12 12

Note 20 - Commitments

Note 20 - Commitments	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	20. Commitments (a) Take or pay contract On October 25, 2019, $3.1 October 31, 2021. March 31, 2021, $2.8 no may (b) Success fees On September 23, 2020 $1.2 (c) Retention agreements In October 2020 The Retention Agreements provide that the Corporation will pay the CEO an employment retention incentive of $100 April 30, 2021 third In addition, the Retention Agreements also provide that the Corporation will pay each of the CEO and COO an amount of up to $125

Note 21 - Subsequent Events

Note 21 - Subsequent Events	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	21. Subsequent events Definitive Agreement to Acquire Grace Therapeutics, Inc. On May 7, 2021, NASDAQ Communication On May 17, 2021 May 11, 2021, $1.00 5550 May 10, 2021,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation These consolidated financial statements of Acasti Pharma Inc., which include the accounts of its subsidiary have been prepared in accordance with U.S. GAAP. All intercompany transactions and balances are eliminated on consolidation. The following summarizes the principal conditions or events relevant to the Corporation's going concern assessment, which primarily considers the period of one The Corporation has incurred operating losses and negative cash flows from operations since its inception. In prior years there was substantial doubt regarding the Corporation's ability to realize its assets and discharge its liabilities and commitments in the ordinary course of business. During year ended March 31, 2021, $59.3 March 31, 2021 $60.7 $1.6 March 31, 2021 The Corporation's ability to continue as a going concern is dependent upon its ability to achieve a successful strategic alternative and ultimately generate cashflows to meet its obligations. To date, the Corporation has financed its operations primarily through public offerings of common shares, private placements, and the proceeds from research tax credits, and will require additional financing in the future. Refer to note 21 no not no one
Use of Estimates, Policy [Policy Text Block]	Significant accounting policies, estimates and judgments: The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may Estimates are based on management's best knowledge of current events and actions that management may Estimates and assumptions include the measurement of derivative warrant liabilities ( note 10 note 15 6 7 20
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Functional and reporting currency: Effective March 31, 2020, The Corporation's functional currency is the Canadian dollar. The effects of exchange rate fluctuations on translating foreign currency monetary assets and liabilities into Canadian dollars are included in the statement of loss and comprehensive loss as foreign exchange gain/loss. Expense transactions are translated into the U.S. dollar reporting currency at the average exchange rate during the period, and assets and liabilities are translated at end of period exchange rates, except for equity transactions, which are translated at historical exchange rates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents: Cash and cash equivalents comprise cash balances and highly liquid investments purchased with original maturities of three
Marketable Securities, Policy [Policy Text Block]	Investments: The Corporation's investments consist of term deposits and are classified as held-to-maturity securities. These investments are recorded at amortized cost. Investments with original maturities exceeding three one
Receivable [Policy Text Block]	Receivables: Receivables are classified at amortized cost and recorded at the outstanding amount net of any provisions for uncollectible amount.
Deferred Charges, Policy [Policy Text Block]	Deferred Financing Costs: Deferred financing costs consists of fees charged by underwriters, attorneys, accountants, and other fees directly attributable to future issuances of shares. Provided these costs are determined to be recoverable, these costs are deferred and charged subsequently against the gross proceeds of the related equity transaction when it occurs. If at such time, the Corporation deems that these costs are no
Assets Held For Sale Policy [Policy Text Block]	Assets held for sale: Assets that are classified as held for sale are measured at the lower of their carrying amount or fair value less expected selling costs (“estimated selling price”) with a loss recognized to the extent that the carrying amount exceeds the estimated selling price. The classification is applicable at the date upon which the sale of assets is probable, and the assets are available for immediate sale in their present condition. Assets once classified as held for sale, are not
Property, Plant and Equipment, Policy [Policy Text Block]	Equipment: (i) Recognition and measurement: Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment and are recognized net within operating expenses in the Consolidated Statement of Loss and Comprehensive Loss. (ii) Subsequent costs: The costs of the day-to-day servicing of equipment are recognized in profit or loss as incurred. (iii) Depreciation: Depreciation is recognized in profit or loss on either a straight-line basis or a declining basis over the estimated useful lives of each part of an item of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets not The estimated useful lives and rates for the current and comparative periods are as follows: Assets Method Period/Rate Furniture and office equipment Declining balance 20% to 30% Computer equipment Declining balance 30% Laboratory equipment Declining balance 30% Production equipment Declining balance 10% to 30% Depreciation methods, useful lives and residual values are reviewed periodically and adjusted prospectively if appropriate.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible assets: Intellectual property and licenses that are acquired by the Corporation from a third Amortization group Amortization is calculated over the cost of the intangible asset less its residual value. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows: Assets Period (years) Patents 20 License 8 to 14 Subsequent expenditure: Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures, including expenditure on internally generated goodwill and brands, are recognized in profit or loss as incurred.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and developments expenditures are expensed as incurred. These costs primarily consist of employees' salaries and benefits related to research and development activities, contractors and consultants that conduct the Corporation's clinical trials, independent auditors and consultants to perform investigation activities on behalf of the Corporation, laboratory material and small equipment, clinical trial materials, stock-based compensation expense, and other non-clinical costs and regulatory fees. Advance payments for goods and services that will be used in future research and development are recognized in prepaids or other assets and are expensed when the services are performed, or the goods are used.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets: The Corporation reviews the recoverability of its long-lived assets whenever events or changes in circumstances indicate that it is carrying amount may not first $5,703 March 31, 2021, nil March 31, 2020.
Share-based Payment Arrangement [Policy Text Block]	Stock based compensation: The Corporation has in place a stock option plan for directors, officers, employees, and consultants of the Corporation, with grants under the stock option plan approved by the Corporation's Board of Directors. The plan provides for the granting of options to purchase Common Shares and the exercise price of each option equals the closing trading price of Common Shares on the day prior to the grant. The terms and conditions for acquiring and exercising options are set by the Corporation's Board of Directors in accordance with and subject to the terms and conditions of the stock option plan. The Corporation measures the cost of such awards based on the fair value of the award at grant date, net of estimated forfeiture, and recognizes stock-based compensation expense in the Consolidated Statements of Loss and Comprehensive Loss on a graded vesting basis over the requisite service period. The requisite service period equals the vesting periods of the awards. The fair value of options is estimated for each tranche of an award that vests on a graded basis. The fair value of options is estimated using the Black-Scholes option pricing model, which uses various inputs including estimated fair value of the Common Shares at the grant date, expected term, estimated volatility, risk-free interest rate and expected dividend yields of the Common Shares. The Corporation applies an estimated forfeiture rate derived from historical employee termination behaviour. If the actual forfeitures differ from those estimated by management, adjustment to compensation expense may Non-employee stock-based compensation transactions in which the Corporation receives goods or services as consideration for its own equity instruments are accounted for as stock-based compensation transactions. The Corporation establishes the fair value at the grant date for non-employee awards and measures the fair value based on the fair value of equity instruments issued. The fair value of a non-employee award is estimated using the Black-Scholes option pricing model, which uses various inputs including estimated fair value of the Common Shares at the grant date, contractual term, estimated volatility, risk-free interest rate and expected dividend yields of the Common Shares.
Government Grants [Policy Text Block]	Government grants: Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Corporation has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Grants that compensate the Corporation for expenses incurred are recognized in profit or loss in reduction thereof on a systematic basis in the same years in which the expenses are recognized. Grants that compensate the Corporation for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset.
Lessee, Leases [Policy Text Block]	Leases: Adoption of Topic 842 On April 1, 2019, 842. no April 1, 2019, 842 Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may not not The Corporation has elected not one not March 31, 2020, $147. two 8%. $80
Income Tax, Policy [Policy Text Block]	Income tax: Income tax expense comprises current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they relate to items recognized directly in equity or in other comprehensive income. Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is recognized in respect of temporary differences between the carrying amounts (tax base) of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax assets and liabilities are measured at the tax rate expected to apply when the underlying asset or liability is realised (settled) based on the rates that are enacted at the reporting date. Deferred tax assets and liabilities are offset if the Corporation has the right to set off the amount owed by with the amount owed by the other party, the Corporation intends to set off and the offset right is enforceable at law. A deferred tax asset is recognized for unused tax losses and tax credits, reduced by a valuation allowance to the extent that it is more likely than not not
Earnings Per Share, Policy [Policy Text Block]	Earnings per share: The Corporation presents basic and diluted earnings per share ( EPS
Segment Reporting, Policy [Policy Text Block]	Segment reporting: An operating segment is a component of the Corporation that engages in business activities from which it may one one $156 March 31, 2020 - $1,510 third
Debt, Policy [Policy Text Block]	Convertible Debentures: The unsecured convertible debentures that existed in the financial statements for the year ended March 31, 2020, February 2020. not not not
Derivatives, Policy [Policy Text Block]	Derivative financial instruments: The Corporation has issued warrants of which some are accounted for as liability-classified derivatives over its own equity. Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit and loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and all changes in their fair value are recognized immediately in profit or loss as a component of financial expenses.
Stockholders' Equity, Policy [Policy Text Block]	Other equity instruments Warrants that do not
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Certain of the Corporation's accounting policies and disclosures require the determination of fair value, for both financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial assets and liabilities: In establishing fair value, the Corporation uses a fair value hierarchy based on levels as defined below: · Level 1: · Level 2: · Level 3: no The Corporation has determined that the carrying values of its short-term financial assets and liabilities (cash and cash equivalents, short-term investments and trade and other payables) approximate their fair value given the short-term nature of these instruments. The Corporation measured its derivative warrant liabilities at fair value on a recurring basis using level 3 .

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Property, Plant and Equipment, Useful Lives and Rates [Table Text Block]	Assets Method Period/Rate Furniture and office equipment Declining balance 20% to 30% Computer equipment Declining balance 30% Laboratory equipment Declining balance 30% Production equipment Declining balance 10% to 30%
Schedule of Intangible Assets, Useful Life [Table Text Block]	Assets Period (years) Patents 20 License 8 to 14

Note 4 - Receivables (Tables)

Note 4 - Receivables (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	March 31, 2021 March 31, 2020 Notes $ $ Sales tax receivables 160 301 Government assistance 8 339 209 Interest receivable 13 11 Other receivables 18 25 Total receivables 530 546

Note 5 - Short-term Investmen_2

Note 5 - Short-term Investments (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Marketable Securities [Table Text Block]	March 31, 2021 March 31, 2020 $ $ Term deposits issued in US currency earning interest at ranges between 0.23% and 0.40% and maturing on various dates from June 22, 2021 to July 27, 2021 7,542 - Term deposits issued in CAD currency earning interest at ranges between 0.58% and 0.67% and maturing on various dates from April 16, 2021 to July 27, 2021 2,247 - Total investments 9,789 - Short-term investments 9,789 - Investments - -

Note 7 - Assets Held for Sale (

Note 7 - Assets Held for Sale (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	March 31, March 31, $ $ Other assets 387 668 Equipment 381 1,910 768 2,578 March 31, 2021 Cost Accumulated Impairment Net book $ $ $ $ Furniture and office equipment 17 (5 ) - 12 Computer equipment 148 (30 ) (54 ) 64 Laboratory equipment 756 (436 ) (171 ) 149 Production equipment 2,538 (1,023 ) (1,359 ) 156 3,459 (1,494 ) (1,584 ) 381 March 31, 2020 Cost Accumulated Net book value $ $ $ Furniture and office equipment 15 3 12 Computer equipment 64 18 46 Laboratory equipment 684 343 341 Production equipment 2,341 830 1,511 3,104 1,194 1,910

Note 8 - Government Assistance

Note 8 - Government Assistance (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Government Assistance [Table Text Block]	March 31, March 31, $ $ Investment tax credit 339 182 Government grant - 27 Total government assistance 339 209
Summary of Tax Credit Carryforwards [Table Text Block]	March 31, 2021 Federal Provincial $ $ Tax losses carried forward 2028 568 568 2029 1,296 1,290 2030 1,649 1,642 2031 1,800 1,784 2032 1,476 1,453 2033 2,864 2,864 2034 3,658 3,549 2035 4,374 4,374 2036 6,435 6,337 2037 398 394 2038 13,803 13,748 2039 32,252 32,209 2040 23,451 23,315 2041 14,279 14,279 108,303 107,808 Research and development expenses, without time limitation 19,905 21,203 Tax credit carry forwards 2,968 - Other deductible temporary differences, without time limitation 8,249 -
Investment Tax Credit Carryforward [Member]
Notes Tables
Summary of Tax Credit Carryforwards [Table Text Block]	$ 2029 9 2030 23 2031 36 2032 343 2033 351 2034 347 2035 413 2036 228 2037 251 2038 180 2039 247 2040 369 2041 170 2,967

Note 9 - Trade and Other Paya_2

Note 9 - Trade and Other Payables (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	March 31, 2021 March 31, 2020 $ $ Trade payables 115 1,713 Accrued liabilities and other payables 607 4,247 Employee salaries and benefits payable 771 1,359 Total trade and other payables 1,493 7,319

Note 10 - Derivative Warrant _2

Note 10 - Derivative Warrant Liabilities (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Warrants issued May 2018 Warrants issued December 27, 2017 March 31, March 31, March 31, March 31, $ $ $ $ Balance – beginning of year 1,146 6,177 1,247 6,005 Issued during the year - - Amount transferred to Equity - (6,072 ) - (4,770 ) Change in fair value 1,252 1,115 1,174 1 Translation effect 199 (74 ) 201 (11 ) Balance – end of year 2,597 1,146 2,622 1,247 Fair value per warrant issuable 0.39 0.17 0.37 0.18
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Warrant liabilities issued May 2018 Warrant liabilities issued December 27, 2017 March 31, $ March 31, $ March 31, March 31, Exercise price CAD $1.31 CAD $1.31 USD $1.26 USD $1.26 Share price CAD $0.76 CAD $0.53 USD $0.60 USD $0.38 Risk-free interest 1.39 % 0.66 % 0.92 % 0.37 % Contractual life (years) 2.11 3.11 1.74 2.74 Expected volatility 156.00 % 107.59 % 171.12 % 125.03 %

Note 11 - Unsecured Convertib_2

Note 11 - Unsecured Convertible Debentures (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Convertible Debt [Table Text Block]	Liability component Equity component Total Private Placement $ $ $ Balance at March 31, 2019 1,361 220 1,581 Accretion of interest on convertible debenture 145 - 145 Translation effect 50 - 50 Shares issued upon exercise of warrants - (33 ) (33 ) Payment upon maturity of debentures (1,556 ) - (1,556 ) Balance at March 31, 2020 - 187 187

Note 12 - Capital and Other C_2

Note 12 - Capital and Other Components of Equity (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	March 31, 2021 March 31, 2020 Number Amount Number Amount $ $ Liability May 2018 public offering warrants 2018 (i) 6,593,750 2,597 6,593,750 1,146 Series December 2017 U.S. public offering warrants 2017 (ii) 7,072,962 2,622 7,072,962 1,247 13,666,712 5,219 13,666,712 2,393 Equity Public offering warrants Public offering broker warrants May 2018 (iii) 1 - 222,976 89 Public offering U.S. broker warrants December 2017 (iv) 259,121 161 259,121 161 Public offering warrants February 2017 (v) 1,723,934 631 1,723,934 631 1,983,056 792 2,206,031 881

Note 14 - Financial Expenses (T

Note 14 - Financial Expenses (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	March 31, March 31, $ $ Foreign exchange gain (loss) (676) (2 ) Interest payable on convertible debenture - (102 ) Accretion of interest on convertible debenture - (145 ) Financing costs (264 ) (46 ) Interest income 107 336 Change in fair value of warrant liabilities (2,426) (1,116 ) Financial expenses (3,259) (1,075 )

Note 15 - Stock Based Compens_2

Note 15 - Stock Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted average Weighted average CAD $ CAD $ Outstanding, March 31, 2019 4,046,677 1.25 0.81 Granted 6,140,517 0.85 0.85 Exercised (30,874 ) 0.81 0.79 Forfeited (212,334 ) 1.62 1.16 Expired (7,500 ) 6.50 3.02 Outstanding, March 31, 2020 9,936,486 1.00 0.83 Granted - - - Exercised (241,750) 0.62 0.47 Forfeited (2,399,817) 0.90 0.74 Expired - - - Outstanding, March 31, 2021 7,294,919 1.04 0.87 Exercisable at end of year 5,025,583 1.17 0.93 March 31, March 31, Weighted average fair value of the options granted to employees and directors of the Corporation - CAD$0.85
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	March 31, March 31, $ $ Research and development expenses 353 443 General and administrative expenses 828 1,217 Sales and marketing expenses (7) 293 1,174 1,953
Schedule of Nonvested Option Activity [Table Text Block]	Number of Weighted average CAD ($) Non- vested, March 31, 2020 6,764,252 0.83 Options granted - - Options vested 1,720,280 0.83 Options forfeited and cancelled 2,774,636 0.90 Non- vested, March 31, 2021 2,269,336 0.76
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	March 31, 2020 Exercise price $ 0.85 Share price $ 1.09 Dividend — Risk-free interest 0.88 % Estimated life (years) 5.71 Expected volatility 99.11
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	March 31, 2021 Exercise price CAD Weighted average remaining contractual life Number of options outstanding Number of options exercisable $ 0.53 – 0.65 8.99 2,418,167 988,167 $ 0.66 – 1.02 7.25 1,527,573 1,300,529 $ 1.03 – 1.42 8.04 1,680,058 1,067,766 $ 1.43 – 1.61 2.11 525,000 525,000 $ 1.62 – 1.71 5.90 108,333 108,333 $ 1.72 – 1.88 6.20 737,500 737,500 $ 1.89 – 3.25 2.16 262,500 262,500 $ 3.26 – 4.65 1.17 22,500 22,500 $ 4.66 – 4.80 1.38 13,288 13,288 7.31 7,294,919 5,025,583

Note 17 - Supplemental Cash F_2

Note 17 - Supplemental Cash Flow Disclosure (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Cash Flow, Operating Capital [Table Text Block]	March 31, March 31, $ $ Receivables 58 581 Prepaid expenses 672 (185 ) Trade and other payables (6,701) (3,389 ) Total changes in working capital items (5,971) (2,993 )
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	March 31, March 31, $ $ ATM transaction costs included in trade and other payables 18 - Shares issued as settlement - 738 Deferred financing costs reclassified to Equity (23) 40 Fair value of derivative warrants liability reclassified to equity - 10,691

Note 18 - Income Taxes (Tables)

Note 18 - Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	March 31, March 31, $ $ Loss before income taxes (19,678) (25,513 ) Basic combined Canadian statutory income tax rate 1 26.50% 26.58 % Computed income tax recovery (5,105) (6,781 ) Increase resulting from: Non-deductible stock-based compensation 311 519 Non-deductible change in fair value of warrants 643 205 Change in valuation allowance 4,162 6,004 Other – Foreign exchange (11) 20 Other - 33 Total tax (recovery) expense - -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	March 31, 2021 March 31, 2020 $ $ Deferred tax assets Tax losses carried forward 28,643 22,052 Research and development expenses 5,424 4,544 Property, plan and equipment 933 324 Intangible assets - 1 Financing expenses 1,167 998 Tax credit carry forwards 2,968 2,468 Other temporary differences 86 76 Deferred tax assets 39,221- 30,463 Deferred tax liabilities Tax basis of unsecured convertible debentures in excess of carrying value - - Deferred tax liabilities - - Valuation allowance (39,221) (30,463 ) Net deferred tax assets - -
Summary of Tax Credit Carryforwards [Table Text Block]	March 31, 2021 Federal Provincial $ $ Tax losses carried forward 2028 568 568 2029 1,296 1,290 2030 1,649 1,642 2031 1,800 1,784 2032 1,476 1,453 2033 2,864 2,864 2034 3,658 3,549 2035 4,374 4,374 2036 6,435 6,337 2037 398 394 2038 13,803 13,748 2039 32,252 32,209 2040 23,451 23,315 2041 14,279 14,279 108,303 107,808 Research and development expenses, without time limitation 19,905 21,203 Tax credit carry forwards 2,968 - Other deductible temporary differences, without time limitation 8,249 -
Summary of Income Tax Contingencies [Table Text Block]	March 31, March 31, $ $ Beginning of year: Increase (decrease) resulting from: Positions taken in the current year - 164 Change in valuation allowance - (164 ) End of year - -

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Cash, Cash Equivalents, and Short-term Investments, Total	$ 60,700,000
Liabilities, Current, Total	1,579,000	$ 7,395,000
Asset Impairment Charges, Total	5,703,000	0
Operating Lease, Right-of-Use Asset	$ 86,000	147,000
Lessee, Operating Lease, Term of Contract (Year)	2 years
Lessee, Operating Lease, Discount Rate	8.00%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	$ 80,000
Number of Reportable Segments	1
Assets, Total	$ 62,458,000	22,853,000
FRANCE
Assets, Total	156,000	1,510,000
At-the-market Offering [Member]
Proceeds from Issuance of Common Stock, Net	$ 59,300,000	$ 7,000,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives and Rates of Equipment (Details)	12 Months Ended
	Mar. 31, 2021
Furniture and Fixtures [Member] | Minimum [Member]
Rate	20.00%
Furniture and Fixtures [Member] | Maximum [Member]
Rate	30.00%
Computer Equipment [Member]
Rate	30.00%
Laboratory Equipment [Member]
Rate	30.00%
Production Equipment [Member] | Minimum [Member]
Rate	10.00%
Production Equipment [Member] | Maximum [Member]
Rate	30.00%

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Intangible Assets (Details)	12 Months Ended
	Mar. 31, 2021
Patents [Member]
Patents (Year)	20 years
Licensing Agreements [Member] | Minimum [Member]
Patents (Year)	8 years
Licensing Agreements [Member] | Maximum [Member]
Patents (Year)	14 years

Note 4 - Receivables - Receivab

Note 4 - Receivables - Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Sales tax receivables	$ 160	$ 301
Government assistance	339	209
Interest receivable	13	11
Other receivables	18	25
Total receivables	$ 530	$ 546

Note 5 - Short-term Investmen_3

Note 5 - Short-term Investments - Marketable Securities (Details) $ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CAD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2020CAD ($)
Total Investments	$ 9,789
Short-term investments	9,789
Investments
Deposits [Member]
Total Investments	$ 7,542
Canadian Deposits [Member]
Total Investments		$ 2,247

Note 5 - Short-term Investmen_4

Note 5 - Short-term Investments - Marketable Securities (Details) (Parentheticals)	Mar. 31, 2021	Mar. 31, 2020
Deposits [Member] | Minimum [Member]
Investment, interest	0.23%	0.23%
Investment, maturity date	Jun. 22, 2021	Jun. 22, 2021
Deposits [Member] | Maximum [Member]
Investment, interest	0.40%	0.40%
Investment, maturity date	Jul. 27, 2021	Jul. 27, 2021
Canadian Deposits [Member] | Minimum [Member]
Investment, interest	0.58%	0.58%
Investment, maturity date	Apr. 16, 2021	Apr. 16, 2021
Canadian Deposits [Member] | Maximum [Member]
Investment, interest	0.67%	0.67%
Investment, maturity date	Jul. 27, 2021	Jul. 27, 2021

Note 6 - Impairment Loss Inta_2

Note 6 - Impairment Loss Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Impairment of Intangible Assets, Finite-lived	$ (3,706)	$ 3,706
Amortization of Intangible Assets, Total		$ 781	$ 1,910

Note 7 - Assets Held for Sale_2

Note 7 - Assets Held for Sale (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Impairment of Other Assets and Prepaids	$ 413
Depreciation, Total	$ 143	$ 410

Note 7 - Assets Held for Sale -

Note 7 - Assets Held for Sale - Summary of Assets Held for Sale (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disposal Group, Including Discontinued Operation, Assets, Current, Total	$ 768	$ 2,578
Equipment held-for-sale, impairment loss	(1,584)
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Other assets	387	668
Equipment	381	1,910
Disposal Group, Including Discontinued Operation, Assets, Current, Total	768	2,578
Equipment held-for-sale, cost	3,459	3,104
Equipment held-for-sale, accumulated depreciation	(1,494)	1,194
Equipment held-for-sale, impairment loss	(1,584)
Equipment held-for-sale, net book value	381	1,910
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Furniture and Office Equipment [Member]
Equipment held-for-sale, cost	17	15
Equipment held-for-sale, accumulated depreciation	(5)	3
Equipment held-for-sale, impairment loss
Equipment held-for-sale, net book value	12	12
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Computer Equipment [Member]
Equipment held-for-sale, cost	148	64
Equipment held-for-sale, accumulated depreciation	(30)	18
Equipment held-for-sale, impairment loss	(54)
Equipment held-for-sale, net book value	64	46
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Laboratory Equipment [Member]
Equipment held-for-sale, cost	756	684
Equipment held-for-sale, accumulated depreciation	(436)	343
Equipment held-for-sale, impairment loss	(171)
Equipment held-for-sale, net book value	149	341
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Production Equipment [Member]
Equipment held-for-sale, cost	2,538	2,341
Equipment held-for-sale, accumulated depreciation	(1,023)	830
Equipment held-for-sale, impairment loss	(1,359)
Equipment held-for-sale, net book value	$ 156	$ 1,511

Note 8 - Government Assistanc_2

Note 8 - Government Assistance (Details Textual) $ in Thousands, $ in Thousands	1 Months Ended		12 Months Ended
	Oct. 31, 2020CAD ($)	Sep. 30, 2019CAD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Proceeds from NRC IRAP			$ 79
Maximum [Member]
Award in Non-dilutive and Non-repayable Funding From NRC IRAP	$ 326,357	$ 750,000
Research and Development Expense [Member]
Government Assistance			$ 127	$ 149

Note 8 - Government Assistanc_3

Note 8 - Government Assistance - Government Assistance (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Investment tax credit	$ 339	$ 182
Government grant		27
Total government assistance	$ 339	$ 209

Note 8 - Government Assistanc_4

Note 8 - Government Assistance - Unrecognized Federal Tax Credits Expirations (Details) - Investment Tax Credit Carryforward [Member] $ in Thousands	Mar. 31, 2021USD ($)
Tax losses carried forward	$ 2,967
Tax Year 2029 [Member]
Tax losses carried forward	9
Tax Year 2030 [Member]
Tax losses carried forward	23
Tax Year 2031 [Member]
Tax losses carried forward	36
Tax Year 2032 [Member]
Tax losses carried forward	343
Tax Year 2033 [Member]
Tax losses carried forward	351
Tax Year 2034 [Member]
Tax losses carried forward	347
Tax Year 2035 [Member]
Tax losses carried forward	413
Tax Year 2036 [Member]
Tax losses carried forward	228
Tax Year 2037 [Member]
Tax losses carried forward	251
Tax Year 2038 [Member]
Tax losses carried forward	180
Tax Year 2039 [Member]
Tax losses carried forward	247
Tax Year 2040 [Member]
Tax losses carried forward	369
Tax Year 2041 [Member]
Tax losses carried forward	$ 170

Note 9 - Trade and Other Paya_3

Note 9 - Trade and Other Payables - Trade and Other Payables (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Trade payables	$ 115	$ 1,713
Accrued liabilities and other payables	607	4,247
Employee salaries and benefits payable	771	1,359
Total trade and other payables	$ 1,493	$ 7,319

Note 10 - Derivative Warrant _3

Note 10 - Derivative Warrant Liabilities (Details Textual) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Millions	May 14, 2018USD ($)shares	May 14, 2018CAD ($)$ / sharesshares	May 09, 2018USD ($)shares	May 09, 2018CAD ($)$ / sharesshares	Dec. 27, 2017USD ($)$ / sharesshares	Mar. 31, 2021$ / shares	Mar. 31, 2021USD ($)$ / sharesshares		Mar. 31, 2020shares
Class of Warrant or Right, Outstanding (in shares)							1,983,056		2,206,031
Derivative Liability, 5 Percent Increase in Volatility, Gain | $							$ 241
Derivative Liability, 5 Percent Decrease in Volatility, Loss | $							257
Derivative Liability, 5 Percent Increase Currency, Gain | $							$ 129
Warrants Issued in May 2018 [Member]
Class of Warrant or Right, Outstanding (in shares)				9,530,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares				$ 1.31		$ 1.31
Over-Allotment Option Warrants Issued in May 2018 [Member]
Class of Warrant or Right, Outstanding (in shares)		1,429,500					6,593,750	[1]	6,593,750	[1]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares		$ 1.31
Warrants Issued December 27, 2017 [Member]
Class of Warrant or Right, Outstanding (in shares)					8,910,891		7,072,962	[2]	7,072,962	[2]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)					1		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares							$ 1.26
Over-Allotment Option Warrants Issued December 2017 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares					$ 1.26
Proceeds from Issuance of Warrants | $					$ 0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					892,044
Public Offering [Member]
Number of Units Issued During Period (in shares)			9,530,000	9,530,000	9,900,990
Price Per Unit Issued (in CAD per share) | (per share)				$ 1.05	$ 1.01
Proceeds from Issuance or Sale of Equity, Total			$ 7,800	$ 10	$ 10,000
Stock Issued During Period, Shares, New Issues (in shares)			9,530,000	9,530,000	9,900,990
Over-Allotment Option [Member]
Number of Units Issued During Period (in shares)	1,429,500	1,429,500
Price Per Unit Issued (in CAD per share) | $ / shares		$ 1.05
Proceeds from Issuance or Sale of Equity, Total	$ 1,100	$ 1.5
Stock Issued During Period, Shares, New Issues (in shares)	1,429,500	1,429,500
[1]	Warrant to acquire one Common Share at an exercise price of CAD $1.31, expiring on May 9, 2023.
[2]	Warrant to acquire one Common Share at an exercise price of $1.26, expiring on December 27, 2022.

Note 10 - Derivative Warrant _4

Note 10 - Derivative Warrant Liabilities - Changes in Fair Value (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Warrants Issued in May 2018 [Member]
Balance – beginning of year	$ 1,146	$ 6,177
Issued during the year
Amount transferred to Equity		(6,072)
Change in fair value	1,252	1,115
Translation effect	199	(74)
Balance – end of year	$ 2,597	$ 1,146
Fair value per warrant issuable (in dollars per share)	$ 0.39	$ 0.17
Warrants Issued December 27, 2017 [Member]
Balance – beginning of year	$ 1,247	$ 6,005
Issued during the year
Amount transferred to Equity		(4,770)
Change in fair value	1,174	1
Translation effect	201	(11)
Balance – end of year	$ 2,622	$ 1,247
Fair value per warrant issuable (in dollars per share)	$ 0.37	$ 0.18

Note 10 - Derivative Warrant _5

Note 10 - Derivative Warrant Liabilities - Assumptions (Details)	Mar. 31, 2021	Mar. 31, 2020
Measurement Input, Exercise Price [Member] | Warrants Issued in May 2018 [Member]
Derivative warrant liability, measurement input	1.31	1.31
Measurement Input, Exercise Price [Member] | Warrants Issued December 27, 2017 [Member]
Derivative warrant liability, measurement input	1.26	1.26
Measurement Input, Share Price [Member] | Warrants Issued in May 2018 [Member]
Derivative warrant liability, measurement input	0.76	0.53
Measurement Input, Share Price [Member] | Warrants Issued December 27, 2017 [Member]
Derivative warrant liability, measurement input	0.6	0.38
Measurement Input, Risk Free Interest Rate [Member] | Warrants Issued in May 2018 [Member]
Derivative warrant liability, measurement input	0.0139	0.0066
Measurement Input, Risk Free Interest Rate [Member] | Warrants Issued December 27, 2017 [Member]
Derivative warrant liability, measurement input	0.0092	0.0037
Measurement Input, Expected Term [Member] | Warrants Issued in May 2018 [Member]
Derivative warrant liability, measurement input	2.11	3.11
Measurement Input, Expected Term [Member] | Warrants Issued December 27, 2017 [Member]
Derivative warrant liability, measurement input	1.74	2.74
Measurement Input, Price Volatility [Member] | Warrants Issued in May 2018 [Member]
Derivative warrant liability, measurement input	1.56	1.0759
Measurement Input, Price Volatility [Member] | Warrants Issued December 27, 2017 [Member]
Derivative warrant liability, measurement input	1.7112	1.2503

Note 11 - Unsecured Convertib_3

Note 11 - Unsecured Convertible Debentures (Details Textual) $ in Thousands, $ in Millions	Feb. 21, 2017USD ($)shares	Feb. 21, 2017CAD ($)shares
Warrants Issued in Connection with Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,052,630	1,052,630
Unsecured Convertible Debentures [Member]
Debt Instrument, Face Amount	$ 1,522	$ 2

Note 11 - Unsecured Convertib_4

Note 11 - Unsecured Convertible Debentures - Liability and Equity Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Payment upon maturity of debentures		$ (1,556)
Unsecured Convertible Debentures [Member]
Beginning balance, liability component		1,361
Beginning balance, equity component	187	220
Beginning balance, total private placement	$ 187	1,581
Accretion of interest on convertible debenture		145
Translation effect		50
Shares issued upon exercise of warrants		(33)
Payment upon maturity of debentures		(1,556)
Ending balance, liability component
Ending balance, equity component		187
Ending balance, total private placement		$ 187

Note 12 - Capital and Other C_3

Note 12 - Capital and Other Components of Equity (Details Textual)	Jun. 29, 2020USD ($)	Feb. 14, 2019USD ($)shares	Mar. 31, 2021$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2021$ / sharesshares	May 09, 2018$ / sharesshares	Dec. 27, 2017shares
At-the-market Sales Agreement, Common Stock, Maximum Amount | $	$ 75,000,000	$ 30,000,000
At-the-market Sales Agreement, Term (Year)		3 years
At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales	3.00%
Write Off of Deferred Financing Costs of At-the-Market Program | $				$ 264,000
Proceeds from Warrant Exercises | $				$ 183,000	$ 7,706,000
Warrants Issued in May 2018 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1			1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares			$ 1.31				$ 1.31
Class of Warrant or Right, Exercised During Period (in shares)				222,975
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ / shares				$ 0.83
Proceeds from Warrant Exercises | $				$ 183,000
Warrants Issued December 27, 2017 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1			1		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares						$ 1.26
Class of Warrant or Right, Exercised During Period (in shares)					52,288
Stock Issued During Period, Shares, Warrant Excercises (in shares)					136,013
Broker Warrants Issued May 2018 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares			$ 1.05
Broker Warrants Issued December 2017 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares						$ 1.2625
Class of Warrant or Right, Exercised During Period (in shares)					235,929
Warrants Issued in Connection with Public Offering February 2017 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares			$ 2.15
At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		0		117,700,000	4,100,000
Proceeds from Issuance of Common Stock, Net | $				$ 59,300,000	$ 7,000,000
Payments of Stock Issuance Costs | $				$ 2,000,000	$ 291,000
Sale of Stock, Average Price Per Share (in dollars per share) | $ / shares				$ 0.52	$ 1.79
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $				$ 18,000	$ 40,000
Minimum [Member]
At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales		3.00%
Maximum [Member]
At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales		4.00%
Common Class A [Member]
Common Stock, Votes Per Share			1			1
Common Class B [Member]
Common Stock, Votes Per Share			10			10
Common Stock, Dividend Rate, Percentage				5.00%
Common Stock, Conversion Rate into Class A				1
Common Stock, Redemption Price Per Share (in CAD per share) | $ / shares			$ 0.80
Common Stock, Shares, Issued, Total (in shares)			0			0
Common Stock, Shares, Outstanding, Ending Balance (in shares)			0			0
Common Class C [Member]
Common Stock, Dividend Rate, Percentage				5.00%
Common Stock, Conversion Rate into Class A				1
Common Stock, Redemption Price Per Share (in CAD per share) | $ / shares			$ 0.20
Common Stock, Shares, Issued, Total (in shares)			0			0
Common Stock, Shares, Outstanding, Ending Balance (in shares)			0			0
Common Class D and Common Class E [Member]
Common Stock, Conversion Rate into Class A				1
Common Stock, Shares, Issued, Total (in shares)			0			0
Common Stock, Shares, Outstanding, Ending Balance (in shares)			0			0
Common Class D and Common Class E [Member] | Minimum [Member]
Common Stock, Dividend Rate, Percentage				0.50%
Common Class D and Common Class E [Member] | Maximum [Member]
Common Stock, Dividend Rate, Percentage				2.00%

Note 12 - Capital and Other C_4

Note 12 - Capital and Other Components of Equity - Warrants (Details) - USD ($) $ in Thousands		Mar. 31, 2021		Mar. 31, 2020		May 14, 2018	Dec. 27, 2017
Number outstanding (in shares)		1,983,056		2,206,031
Amount		$ 792		$ 881
Over-Allotment Option Warrants Issued in May 2018 [Member]
Number outstanding (in shares)		6,593,750	[1]	6,593,750	[1]	1,429,500
Amount	[1]	$ 2,597		$ 1,146
Warrants Issued December 27, 2017 [Member]
Number outstanding (in shares)		7,072,962	[2]	7,072,962	[2]		8,910,891
Amount	[2]	$ 2,622		$ 1,247
Derivative Liability Warrants [Member]
Number outstanding (in shares)		13,666,712		13,666,712
Amount		$ 5,219		$ 2,393
Broker Warrants Issued May 2018 [Member]
Number outstanding (in shares)	[3]	1		222,976
Amount	[3]			$ 89
Broker Warrants Issued December 2017 [Member]
Number outstanding (in shares)		259,121		259,121
Amount		$ 161		$ 161
Warrants Issued in Connection with Public Offering February 2017 [Member]
Number outstanding (in shares)	[4]	1,723,934		1,723,934
Amount	[4]	$ 631		$ 631
[1]	Warrant to acquire one Common Share at an exercise price of CAD $1.31, expiring on May 9, 2023.
[2]	Warrant to acquire one Common Share at an exercise price of $1.26, expiring on December 27, 2022.
[3]	Warrant to acquire one Common Share o at an exercise price of CAD $1.05, expiring on May 9, 2023.
[4]	Warrant to acquire one Common Share at an exercise price of CAD $2.15, expiring on February 21, 2022.

Note 14 - Financial Expenses -

Note 14 - Financial Expenses - Financial Income (Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Foreign exchange gain (loss)	$ (676)	$ (2)
Interest payable on convertible debenture		(102)
Accretion of interest on convertible debenture		(145)
Financing costs	(264)	(46)
Interest income	107	336
Change in fair value of warrant liabilities	(2,426)	(1,116)
Financial expenses	$ (3,259)	$ (1,075)

Note 15 - Stock Based Compens_3

Note 15 - Stock Based Compensation (Details Textual) $ in Thousands, $ in Thousands	Aug. 26, 2020shares	Apr. 09, 2019shares	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2021CAD ($)shares	Mar. 31, 2020CAD ($)shares
Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | shares	14,533,881	11,719.91
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	15.00%	15.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person			2.00%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total					$ 476	$ 2,802
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 10 days	1 year 127 days
Share-based Payment Arrangement, Expense			$ 1,174	$ 1,953
Stock Option Plan [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person			2.00%
Stock Option Plan [Member] | Related Party [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person			2.00%
Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares) | shares					0	0
Share-based Payment Arrangement, Expense			$ 0	$ 0

Note 15 - Stock-based Compensat

Note 15 - Stock-based Compensation - Activities Within the Stock Option Plan (Details) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Granted, number of options (in shares)
Granted, weighted average fair value (in CAD per share)
Expired, number of options (in shares)
Expired, weighted average exercise price (in CAD per share)
Expired, weighted average fair value (in CAD per share)
Stock Option Plan [Member]
Outstanding, number of options (in shares)	9,936,486	4,046,677
Outstanding, weighted average exercise price (in CAD per share)	$ 1	$ 1.25
Outstanding, weighted average fair value (in CAD per share)	$ 0.83	$ 0.81
Granted, number of options (in shares)		6,140,517
Granted, weighted average exercise price (in CAD per share)		$ 0.85
Granted, weighted average fair value (in CAD per share)		$ 0.85
Exercised, number of options (in shares)	(241,750)	(30,874)
Exercised, weighted average exercise price (in CAD per share)	$ 0.62	$ 0.81
Exercised, weighted average fair value (in CAD per share)	$ 0.47	$ 0.79
Forfeited, number of options (in shares)	(2,399,817)	(212,334)
Forfeited, weighted average exercise price (in CAD per share)	$ 0.90	$ 1.62
Forfeited, weighted average fair value (in CAD per share)	$ 0.74	$ 1.16
Expired, number of options (in shares)		(7,500)
Expired, weighted average exercise price (in CAD per share)		$ 6.50
Expired, weighted average fair value (in CAD per share)		$ 3.02
Outstanding, number of options (in shares)	7,294,919	9,936,486
Outstanding, weighted average exercise price (in CAD per share)	$ 1.04	$ 1
Outstanding, weighted average fair value (in CAD per share)	$ 0.87	0.83
Exercisable, number of options (in shares)	5,025,583
Exercisable, weighted average exercise price (in CAD per share)	$ 1.17
Exercisable, weighted average fair value (in CAD per share)	0.93
Stock Option Plan [Member] | Directors and Employees [Member]
Granted, weighted average fair value (in CAD per share)		$ 0.85

Note 15 - Stock Based Compens_4

Note 15 - Stock Based Compensation - Compensation Expense (Details) - Stock Option Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expense	$ 1,174	$ 1,953
Research and Development Expense [Member]
Share-based Payment Arrangement, Expense	353	443
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense	828	1,217
Selling and Marketing Expense [Member]
Share-based Payment Arrangement, Expense	$ (7)	$ 293

Note 15 - Stock-based Compens_2

Note 15 - Stock-based Compensation - Non-vested Stock Option Activity (Details) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Non-vested, number of options (in shares)	6,764,252
Non-vested, weighted average grant date fair value price (in CAD per share)	$ 0.76	$ 0.83
Granted, number of options (in shares)
Granted, weighted average fair value (in CAD per share)
Options vested (in shares)	1,720,280
Options vested, weighted average grant date fair value price (in CAD per share)		0.83
Options forfeited and cancelled (in shares)	2,774,636
Options forfeited and cancelled, weighted average grant date fair value price (in CAD per share)		$ 0.90
Non-vested, number of options (in shares)	2,269,336	6,764,252
Non-vested, weighted average grant date fair value price (in CAD per share)		$ 0.76

Note 15 - Stock-based Compens_3

Note 15 - Stock-based Compensation - Assumptions (Details) - Share-based Payment Arrangement, Option [Member]	12 Months Ended
	Mar. 31, 2021$ / shares
Exercise price (in CAD per share)	$ 0.85
Share price (in CAD per share)	$ 1.09
Dividend
Risk-free interest	0.88%
Estimated life (years) (Year)	5 years 259 days
Expected volatility	99.11%

Note 15 - Stock-based Compens_4

Note 15 - Stock-based Compensation - Outstanding and Exercisable Options (Details)	12 Months Ended
	Mar. 31, 2021$ / sharesshares
Weighted average remaining contractual life (Year)	7 years 113 days
Number of options outstanding (in shares)	7,294,919
Number of options exercisable (in shares)	5,025,583
Exercise Price Range 1 [Member]
Lower limit, exercise price (in CAD per share) | $ / shares	$ 0.53
Upper limit, exercise price (in CAD per share) | $ / shares	$ 0.65
Weighted average remaining contractual life (Year)	8 years 361 days
Number of options outstanding (in shares)	2,418,167
Number of options exercisable (in shares)	988,167
Exercise Price Range 2 [Member]
Lower limit, exercise price (in CAD per share) | $ / shares	$ 0.66
Upper limit, exercise price (in CAD per share) | $ / shares	$ 1.02
Weighted average remaining contractual life (Year)	7 years 91 days
Number of options outstanding (in shares)	1,527,573
Number of options exercisable (in shares)	1,300,529
Exercise Price Range 3 [Member]
Lower limit, exercise price (in CAD per share) | $ / shares	$ 1.03
Upper limit, exercise price (in CAD per share) | $ / shares	$ 1.42
Weighted average remaining contractual life (Year)	8 years 14 days
Number of options outstanding (in shares)	1,680,058
Number of options exercisable (in shares)	1,067,766
Exercise Price Range 4 [Member]
Lower limit, exercise price (in CAD per share) | $ / shares	$ 1.43
Upper limit, exercise price (in CAD per share) | $ / shares	$ 1.61
Weighted average remaining contractual life (Year)	2 years 40 days
Number of options outstanding (in shares)	525,000
Number of options exercisable (in shares)	525,000
Exercise Price Range 5 [Member]
Lower limit, exercise price (in CAD per share) | $ / shares	$ 1.62
Upper limit, exercise price (in CAD per share) | $ / shares	$ 1.71
Weighted average remaining contractual life (Year)	5 years 328 days
Number of options outstanding (in shares)	108,333
Number of options exercisable (in shares)	108,333
Exercise Price Range 6 [Member]
Lower limit, exercise price (in CAD per share) | $ / shares	$ 1.72
Upper limit, exercise price (in CAD per share) | $ / shares	$ 1.88
Weighted average remaining contractual life (Year)	6 years 73 days
Number of options outstanding (in shares)	737,500
Number of options exercisable (in shares)	737,500
Exercise Price Range 7 [Member]
Lower limit, exercise price (in CAD per share) | $ / shares	$ 1.89
Upper limit, exercise price (in CAD per share) | $ / shares	$ 3.25
Weighted average remaining contractual life (Year)	2 years 58 days
Number of options outstanding (in shares)	262,500
Number of options exercisable (in shares)	262,500
Exercise Price Range 8 [Member]
Lower limit, exercise price (in CAD per share) | $ / shares	$ 3.26
Upper limit, exercise price (in CAD per share) | $ / shares	$ 4.65
Weighted average remaining contractual life (Year)	1 year 62 days
Number of options outstanding (in shares)	22,500
Number of options exercisable (in shares)	22,500
Exercise Price Range 9 [Member]
Lower limit, exercise price (in CAD per share) | $ / shares	$ 4.66
Upper limit, exercise price (in CAD per share) | $ / shares	$ 4.80
Weighted average remaining contractual life (Year)	1 year 138 days
Number of options outstanding (in shares)	13,288
Number of options exercisable (in shares)	13,288

Note 17 - Supplemental Cash F_3

Note 17 - Supplemental Cash Flow Disclosure - Changes in Working Capital Items (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Receivables	$ 58	$ 581
Prepaid expenses	672	(185)
Trade and other payables	(6,701)	(3,389)
Total changes in working capital items	$ (5,971)	$ (2,993)

Note 17 - Supplemental Cash F_4

Note 17 - Supplemental Cash Flow Disclosure - Non-cash Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
ATM transaction costs included in trade and other payables	$ 18
Shares issued as settlement		738
Deferred financing costs reclassified to Equity	(23)	40
Fair value of derivative warrants liability reclassified to equity		$ 10,691

Note 18 - Income Taxes - Reconc

Note 18 - Income Taxes - Reconciliation of Effective Tax Rate (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Loss before income taxes		$ (19,678)	$ (25,513)
Basic combined Canadian statutory income tax rate	[1]	26.50%	26.58%
Computed income tax recovery		$ (5,105)	$ (6,781)
Non-deductible stock-based compensation		311	519
Non-deductible change in fair value of warrants		643	205
Change in valuation allowance		4,162	6,004
Other – Foreign exchange		(11)	20
Other			33
Total tax (recovery) expense
[1]	The Canadian combined statutory income tax rate has decreased due to a reduction in the provincial statutory income tax rate.

Note 18 - Income Taxes - Net De

Note 18 - Income Taxes - Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Tax losses carried forward	$ 28,643	$ 22,052
Research and development expenses	5,424	4,544
Property, plan and equipment	933	324
Intangible assets		1
Financing expenses	1,167	998
Tax credit carry forwards	2,968	2,468
Other temporary differences	86	76
Deferred tax assets	39,221	30,463
Tax basis of unsecured convertible debentures in excess of carrying value
Deferred tax liabilities
Valuation allowance	(39,221)	(30,463)
Net deferred tax assets

Note 18 - Income Taxes - Tax At

Note 18 - Income Taxes - Tax Attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details) $ in Thousands	Mar. 31, 2021USD ($)
Domestic Tax Authority [Member]
Tax losses carried forward	$ 108,303
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Carryforwards, without time limitation	19,905
Domestic Tax Authority [Member] | Tax Credit Carry Forwards [Member]
Carryforwards, without time limitation	2,968
Domestic Tax Authority [Member] | Other Tax Credit Carryforward [Member]
Carryforwards, without time limitation	8,249
Domestic Tax Authority [Member] | Tax Year 2028 [Member]
Tax losses carried forward	568
Domestic Tax Authority [Member] | Tax Year 2029 [Member]
Tax losses carried forward	1,296
Domestic Tax Authority [Member] | Tax Year 2030 [Member]
Tax losses carried forward	1,649
Domestic Tax Authority [Member] | Tax Year 2031 [Member]
Tax losses carried forward	1,800
Domestic Tax Authority [Member] | Tax Year 2032 [Member]
Tax losses carried forward	1,476
Domestic Tax Authority [Member] | Tax Year 2033 [Member]
Tax losses carried forward	2,864
Domestic Tax Authority [Member] | Tax Year 2034 [Member]
Tax losses carried forward	3,658
Domestic Tax Authority [Member] | Tax Year 2035 [Member]
Tax losses carried forward	4,374
Domestic Tax Authority [Member] | Tax Year 2036 [Member]
Tax losses carried forward	6,435
Domestic Tax Authority [Member] | Tax Year 2037 [Member]
Tax losses carried forward	398
Domestic Tax Authority [Member] | Tax Year 2038 [Member]
Tax losses carried forward	13,803
Domestic Tax Authority [Member] | Tax Year 2039 [Member]
Tax losses carried forward	32,252
Domestic Tax Authority [Member] | Tax Year 2040 [Member]
Tax losses carried forward	23,451
Domestic Tax Authority [Member] | Tax Year 2041 [Member]
Tax losses carried forward	14,279
State and Local Jurisdiction [Member]
Tax losses carried forward	107,808
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Carryforwards, without time limitation	21,203
State and Local Jurisdiction [Member] | Tax Credit Carry Forwards [Member]
Carryforwards, without time limitation
State and Local Jurisdiction [Member] | Other Tax Credit Carryforward [Member]
Carryforwards, without time limitation
State and Local Jurisdiction [Member] | Tax Year 2028 [Member]
Tax losses carried forward	568
State and Local Jurisdiction [Member] | Tax Year 2029 [Member]
Tax losses carried forward	1,290
State and Local Jurisdiction [Member] | Tax Year 2030 [Member]
Tax losses carried forward	1,642
State and Local Jurisdiction [Member] | Tax Year 2031 [Member]
Tax losses carried forward	1,784
State and Local Jurisdiction [Member] | Tax Year 2032 [Member]
Tax losses carried forward	1,453
State and Local Jurisdiction [Member] | Tax Year 2033 [Member]
Tax losses carried forward	2,864
State and Local Jurisdiction [Member] | Tax Year 2034 [Member]
Tax losses carried forward	3,549
State and Local Jurisdiction [Member] | Tax Year 2035 [Member]
Tax losses carried forward	4,374
State and Local Jurisdiction [Member] | Tax Year 2036 [Member]
Tax losses carried forward	6,337
State and Local Jurisdiction [Member] | Tax Year 2037 [Member]
Tax losses carried forward	394
State and Local Jurisdiction [Member] | Tax Year 2038 [Member]
Tax losses carried forward	13,748
State and Local Jurisdiction [Member] | Tax Year 2039 [Member]
Tax losses carried forward	32,209
State and Local Jurisdiction [Member] | Tax Year 2040 [Member]
Tax losses carried forward	23,315
State and Local Jurisdiction [Member] | Tax Year 2041 [Member]
Tax losses carried forward	$ 14,279

Note 18 - Income Taxes - Unreco

Note 18 - Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Beginning of year:
Positions taken in the current year		164
Change in valuation allowance		(164)
End of year

Note 20 - Commitments (Details

Note 20 - Commitments (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Oct. 31, 2020	Oct. 25, 2019
Chief Executive Officer [Member]
Retention Incentive Agreement, Continued Employment Until April 30, 2021 or Closing Transaction With Third Party			$ 100
Chief Executive Officer and Chief Operating Officer [Member]
Retention Incentive Agreement, Maximum Conditional Incentives			$ 125
Oppenheimer & Co. Inc. [Member]
Success Fees to be Paid Based on the Outcome of the Strategic Evaluation	$ 1,200
RKO Supply Agreement [Member]
Purchase Obligation, Total				$ 3,100
Purchase Commitment, Remaining Minimum Amount Committed		$ 2,800